Atopic dermatitis (AD) or eczema, is the most common skin disease, characterized by a disturbance of epidermal barrier function culminating in dry skin, itching lesions, IgE-mediated sensitization to food and allergens, chronic relapsing skin inflammation, and a frequent need for long term treatment. The disease affects up to 25% of children and up to 3% of adults, where prevalence has increased 2–3 fold during the last century, particularly in industrialized countries. The 2014 U.S. census estimated that 19,876,883 children were between the ages of 0-5, where 90% of all AD cases begin. AD is often the initial step in the atopic march, which leads to asthma and allergic rhinitis in the majority of afflicted patients. Other complications include frequently occurring bacterial or viral superinfections that lead to systemic antibacterial or antiviral treatment and hospitalization in severe cases. Consequently, there exists a significant impact on quality of life for patients and their families, as patients suffer from social stigmatization, sleep disorders mainly caused by the massive itch, and a higher risk of depression, at an economic cost in the billions.
Rosacea is a chronic, cutaneous inflammatory disease. Most of the skin lesions of rosacea occur on the cheeks, forehead, chin, and nose. Patients also suffer from cutaneous symptoms, such as facial flushing, stinging, pain or burning sensations. Rosacea is estimated to affect over 16 million Americans, with prevalence after age 30, though cases in childhood have been reported. Abnormalities in the innate immune system and neurovascular dysregulation are implicated in the pathophysiology. Various triggering factors, such as demodex colonization, microbial stimuli, UV radiation, heat, and stress drive the development or worsening of symptoms. Severe symptoms of rosacea are responsible for loss in productivity as 88% of patients surveyed have said the disorder has adversely affected their professional interactions, with 51% missing work.
Psoriasis is a chronic immune-mediated inflammatory skin disorder presenting clinically as well-demarcated, raised, erythematous, scaly plaques predominantly affecting the scalp, trunk, and extensor surfaces, tending to have a chronic relapsing and remitting course. Plaque-type psoriasis is the most common form occurring in 85%—95% of affected patients with severity ranging from a few scattered plaques to involvement of almost the entire body surface. The disease affects 1 - 2% of the population worldwide and its mild-to-moderate condition affects approximately 80% of that total, beginning in childhood for almost 1/3 of all cases. Psoriasis in children and adolescents in particular can have a profound long-term impact on their quality of life, with associated comorbidities such as obesity, hypertension, diabetes mellitus, rheumatoid arthritis, Crohn’s disease, and psychiatric disorders, making early diagnosis and management essential. Current treatments are intended for adult patients and are limited in safety and efficacy; most systemic treatments are not approved for use in children and are being used off-label.